Halvorsen Pharma pays $2.1B for Calder Bio. Why the price held.
Yemi Adebayo · 4 min
Yemi Adebayo is a markets reporter at Rounds covering how public equities — biotech, medtech, payors, and digital-health platforms — react to deals, FDA decisions, and clinical readouts.
He spent five years as a sell-side equity analyst at Redfern Securities covering small- and mid-cap biotech before moving to journalism. His morning notes are read by 12,000+ buy-side analysts and PMs.
Yemi specializes in financial analysis.
